S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Bangladesh seeks China help to repatriate Rohingya refugees
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Bangladesh seeks China help to repatriate Rohingya refugees
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Bangladesh seeks China help to repatriate Rohingya refugees
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Bangladesh seeks China help to repatriate Rohingya refugees
pixel
NASDAQ:REGN

Regeneron Pharmaceuticals (REGN) Price Target & Analyst Ratings

$613.61
-1.35 (-0.22%)
(As of 08/5/2022 08:49 PM ET)
Add
Compare
Today's Range
$606.96
$621.63
50-Day Range
$548.35
$692.80
52-Week Range
$538.01
$747.42
Volume
566,700 shs
Average Volume
695,719 shs
Market Capitalization
$66.60 billion
P/E Ratio
12.25
Dividend Yield
N/A
Price Target
$697.85

Regeneron Pharmaceuticals Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 19 Analyst Ratings

Consensus Analyst Price Target

$697.85
13.73% Upside
High Prediction$844.00
Average Prediction$697.85
Low Prediction$536.00
TypeCurrent
8/8/21 to 8/8/22
1 Month Ago
7/9/21 to 7/9/22
3 Months Ago
5/10/21 to 5/10/22
1 Year Ago
8/8/20 to 8/8/21
Consensus Rating
Hold
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
13 Buy rating(s)
12 Buy rating(s)
11 Buy rating(s)
Hold
6 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$697.85$707.43$726.33$670.67
Predicted Upside13.73% Upside10.23% Upside12.06% Upside21.41% Upside
Get Regeneron Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.


REGN Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

REGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Regeneron Pharmaceuticals Stock vs. The Competition

TypeRegeneron PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.47
2.71
2.50
Consensus RatingHoldBuyHold
Predicted Upside13.73% Upside516.78% Upside18.64% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
1424
67.81%
Underperform Votes
676
32.19%
Avg. Outperform Votes
166
66.67%
Avg. Underperform Votes
83
33.33%
Avg. Outperform Votes
840
68.74%
Avg. Underperform Votes
382
31.26%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/4/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Evan Seigerman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform$757.00 ➝ $788.00+26.85%
8/4/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight$619.00 ➝ $625.00+0.59%
7/25/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$630.00+7.49%
7/20/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform$635.00 ➝ $645.00+8.94%
7/12/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Young
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$625.00+2.44%
6/20/2022Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Set Target$635.00+9.30%
6/17/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Akash Tewari
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeSell$536.00-7.74%
6/3/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$750.00 ➝ $735.00+15.95%
5/31/2022Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$680.00 ➝ $760.00+9.70%
4/12/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$700.00 ➝ $745.00+3.13%
2/8/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$754.00 ➝ $728.00+17.49%
2/8/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$825.00 ➝ $775.00+24.53%
2/4/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Christopher Raymond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$690.00 ➝ $692.00+10.96%
1/5/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$675.00 ➝ $575.00-6.78%
1/3/2022Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Aaron Gal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$660.00+4.51%
12/13/2021HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
12/6/2021The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$824.00+29.73%
11/5/2021Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
9/9/2021UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$763.00+14.02%
7/23/2021Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kennen MacKay
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetSector Perform$629.00 ➝ $679.00+15.70%
4/13/2021Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
2/23/2021Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$753.00 ➝ $760.00+65.01%
1/14/2021Smith Barney Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$575.00 ➝ $584.00+12.71%
1/8/2021FIX
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$635.00 ➝ $575.00+19.49%
10/1/2020JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
8/6/2020Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$585.00 ➝ $635.00+1.68%
7/8/2020SunTrust Banks
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$400.00 ➝ $750.00+17.03%
5/27/2020Cfra
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold$557.00 ➝ $549.00+0.88%
3/31/2020Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$455.00-2.34%
12/23/2019Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Dane Leone
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform
10/8/2019Piper Jaffray Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Christopher Raymond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set TargetBuy$435.00+44.63%
9/23/2019Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$355.00 ➝ $403.00+36.21%
(Data available from 8/8/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Regeneron Pharmaceuticals Price Target - Frequently Asked Questions

What is Regeneron Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 19 analysts in the last year, the consensus rating for Regeneron Pharmaceuticals stock is Hold based on the current 2 sell ratings, 6 hold ratings and 11 buy ratings for REGN. The average twelve-month price prediction for Regeneron Pharmaceuticals is $697.85 with a high price target of $844.00 and a low price target of $536.00. Learn more on REGN's analyst rating history.

Do Wall Street analysts like Regeneron Pharmaceuticals more than its competitors?

Analysts like Regeneron Pharmaceuticals less than other Medical companies. The consensus rating for Regeneron Pharmaceuticals is Hold while the average consensus rating for medical companies is Buy. Learn more on how REGN compares to other companies.

Do MarketBeat users like Regeneron Pharmaceuticals more than its competitors?

MarketBeat users like Regeneron Pharmaceuticals more than other Medical companies. 67.81% of MarketBeat users gave Regeneron Pharmaceuticals an outperform vote while medical companies recieve an average of 66.80% outperform votes by MarketBeat users.

Is Regeneron Pharmaceuticals being downgraded by Wall Street analysts?

Over the previous 90 days, Regeneron Pharmaceuticals's stock had 2 downgrades by analysts.

Does Regeneron Pharmaceuticals's stock price have much upside?

According to analysts, Regeneron Pharmaceuticals's stock has a predicted upside of 10.76% based on their 12-month price targets.

What analysts cover Regeneron Pharmaceuticals?

Stock Ratings Reports and Tools

This page (NASDAQ:REGN) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.